Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in therapies for autoimmune diseases with high unmet needs. Its core product, LUPKYNIS (voclosporin), is the first FDA-approved oral treatment for adult lupus nephritis, marketed in the U.S. and licensed internationally. Aurinia develops novel immunosuppressants like AUR200 targeting B cell pathways. The company operates through direct sales and partnerships, leveraging proprietary patents and contract manufacturing to serve patients and healthcare providers globally.
This description was generated via AI from an annual report. Updated about 1 year ago.